Rob Meijer | Chief Executive Officer
Amphera

Rob Meijer, Chief Executive Officer, Amphera

Rob Meijer is CEO of Amphera BV. Amphera B.V., an advanced-clinical-stage biotechnology company, develops dendritic cell therapies for the treatment of cancer. Our lead indication is mesothelioma, a cancer of the lining of the lungs. MesoPher is autologous dendritic cells loaded with our proprietary allogeneic tumour cell lysate PheraLys. PheraLys is a well-characterised, innovative source of a broad-spectrum of Tumour Associated Antigens. Several clinical studies with our lead product candidate MesoPher are ongoing.

Appearances:



Conference Day 1 - Tuesday 31st March 2020 @ 15:00

Clinical stage allogenic dendritic cell-based immunotherapy targeting mesothelioma and pancreatic cancer

last published: 04/Jun/20 08:25 GMT

back to speakers